Effectiveness of deucravacitinib for genital, nail and scalp lesions in patients with psoriasis: a 24-week real-world study.

Autor:	Hagino T; Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan., Onda M; Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan., Saeki H; Department of Dermatology, Nippon Medical School, Tokyo, Japan., Fujimoto E; Fujimoto Dermatology Clinic, Funabashi, Japan., Kanda N; Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
Jazyk:	angličtina
Zdroj:	Clinical and experimental dermatology [Clin Exp Dermatol] 2024 Dec 23; Vol. 50 (1), pp. 130-133.
DOI:	10.1093/ced/llae312
Abstrakt:	Psoriasis is a chronic, complicated inflammatory skin disease. Genital, nail and scalp lesions with psoriasis are difficult to treat and can considerably impair patients' quality of life (QoL). Deucravacitinib, an oral selective tyrosine kinase 2 inhibitor, may represent a novel therapeutic option that could improve these challenging manifestations. To investigate this, we conducted a retrospective study between January 2023 and February 2024, involving 70 patients with psoriasis treated with deucravacitinib 6 mg orally once daily for 24 weeks. We evaluated how many patients achieved a static Physician's Global Assessment (PGA) of Genitalia (sPGA-GTM) score of clear/almost clear (0/1), PGA of Fingernail Psoriasis (PGA-F) 0/1, scalp-specific PGA (ss-PGA) 0/1, static PGA (sPGA) 0/1 and Dermatology Life Quality Index 0/1 at weeks 4, 16 and 24. We also assessed the Psoriasis Area and Severity Index scores. Deucravacitinib improved genital, nail and scalp lesions, as well as systemic eruption and QoL in patients with psoriasis. Deucravacitinib may be a promising treatment option for lesions in difficult-to-treat areas in patients with psoriasis. Competing Interests: Conflicts of interest T.H., H.S. and N.K. have received lecture fees from Bristol Myers Squibb. The other authors declare no conflicts of interest. (© The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu